Zollinger-Ellison Syndrome

What Zollinger-Ellison syndrome is

ZES occurs when a neuroendocrine tumor called a gastrinoma releases excessive gastrin. Gastrin signals the stomach to produce acid. Persistent excess acid can damage the stomach and duodenum, injure the esophagus, and interfere with digestion and absorption.

Gastrinomas most often arise in the duodenum or pancreas, although very small tumors can be difficult to locate. They may be single or multiple and may spread to lymph nodes, liver, bone, or other sites.

ZES is rare. Common reflux disease, peptic ulcer related to Helicobacter pylori, and nonsteroidal anti-inflammatory drug injury are much more frequent. Severe symptoms do not establish a gastrinoma without biochemical and imaging evidence.

Possible symptoms

Excess acid can cause burning or dull upper-abdominal pain, heartburn, sour regurgitation, nausea, vomiting, painful swallowing, or recurrent peptic ulcers. Ulcers may occur in unusual locations, recur after treatment, or develop without H. pylori or NSAID use.

Diarrhea can be prominent and may be the only obvious symptom. Acid reaching the small intestine can interfere with digestive enzymes and fat absorption, causing watery stool, greasy stool, cramps, weight loss, or nutrient deficiency.

Symptoms can improve with acid suppression, which can mask the underlying syndrome. Response to a proton-pump inhibitor does not confirm ZES because ordinary reflux and ulcers also improve.

Emergency warning signs

Use emergency services for vomiting blood, black tar-like stool with weakness or fainting, collapse, severe chest pain, major breathing difficulty, or a sudden severe abdominal pain that does not settle. These can signal bleeding, perforation, heart disease, or another emergency.

Persistent vomiting, inability to swallow fluids, severe dehydration, rapidly worsening pain, fever with a rigid abdomen, or progressive jaundice needs urgent assessment.

A person with known ZES who cannot take prescribed acid-suppression medicine should contact the specialist promptly because uncontrolled acid can recur quickly.

Gastrinomas and cancer risk

Gastrinomas are neuroendocrine tumors. Some remain localized for years, while others spread. Tumor size, site, grade, growth rate, stage, liver involvement, and association with MEN1 affect management.

The term malignant cannot be decided only from the gastrin level. Pathology, imaging, and evidence of spread are needed. Even a small duodenal tumor can be clinically important because of hormone production.

Acid control and cancer control are separate goals. A medicine can control ulcers and diarrhea while the tumor still needs imaging and oncologic follow-up.

The connection with MEN1

A portion of people with ZES have multiple endocrine neoplasia type 1, or MEN1, an inherited tumor-predisposition condition. MEN1 can cause tumors of parathyroid, pituitary, pancreatic, duodenal, and other endocrine tissues.

Clues include a personal or family history of high calcium, kidney stones, pituitary tumors, multiple pancreatic or duodenal neuroendocrine tumors, or young onset. The absence of known family history does not completely exclude MEN1.

Genetic counseling and MEN1 testing are selected from the clinical pattern. A negative consumer DNA result does not replace clinical-grade testing.

Fasting gastrin and stomach acidity

A fasting serum gastrin level is an important first test, but high gastrin has many causes. Proton-pump inhibitors, low stomach acid, autoimmune gastritis, kidney disease, retained stomach tissue after surgery, and other conditions can raise it.

For ZES, gastrin is interpreted together with evidence that the stomach remains acidic. A very high gastrin level in a person whose stomach makes little acid does not have the same meaning as the same level with marked acid secretion.

Fasting instructions, laboratory method, medicine timing, and kidney function affect interpretation. Repeating a carefully prepared test can be more useful than reacting to one unexpected result.

Why proton-pump inhibitors must not be stopped casually

Proton-pump inhibitors, or PPIs, lower stomach acid and can also raise gastrin. Testing may therefore require a specialist plan to adjust medicine and assess acidity.

Stopping a PPI in a person with possible ZES can allow severe acid production, ulcer bleeding, perforation, or pain. Any reduction should be supervised by an experienced gastroenterology team with rescue medication, monitoring, and rapid access to care.

A person should not stop a PPI because an online laboratory instruction says to be medication-free. The diagnostic team must balance test accuracy and safety.

Secretin testing and endoscopy

A secretin stimulation test can help when fasting gastrin and acidity do not provide a clear answer. Gastrin is measured before and after intravenous secretin under a defined protocol. Availability and interpretation vary.

Upper endoscopy can identify ulcers, esophagitis, narrowing, bleeding, or enlarged stomach folds and can collect biopsies for other diagnoses. It may not find a small gastrinoma because many arise outside the lining being viewed.

Stomach-fluid pH or acid-output assessment can provide key context. No single endoscopy finding confirms ZES.

Finding the tumor

After biochemical evidence supports ZES, imaging seeks the gastrinoma and determines extent. Options can include contrast CT, MRI, endoscopic ultrasound, and somatostatin-receptor imaging with a radiolabeled tracer.

Small duodenal tumors can be difficult to see, and multiple methods may be needed. A negative scan does not automatically erase strong biochemical evidence, while an incidental pancreatic spot does not prove it is the source of gastrin.

Imaging choice considers kidney function, radiation, contrast allergy, pregnancy, prior surgery, and whether a result would change surgery or systemic treatment.

Controlling stomach acid

PPIs are the main acid-suppression treatment and may be needed at higher or more frequent doses than for ordinary reflux. The dose is adjusted to control symptoms, heal injury, and prevent complications.

Many people require long-term treatment. Monitoring can include magnesium, vitamin B12, iron, bone health, kidney issues, infection risk, and medicine interactions according to dose, duration, and other conditions.

Benefits of adequate acid control usually outweigh theoretical long-term concerns in active ZES. Stopping effective treatment because of a generalized PPI warning can be dangerous.

Surgery

Surgery may be recommended to remove a localized sporadic gastrinoma when the team believes it can be found and removed safely. The operation depends on whether the tumor is in the duodenum, pancreas, lymph nodes, or another location.

MEN1-associated gastrinomas are often multiple and small, so surgical decisions differ. Removing one visible tumor may not cure hormone excess. Decisions should occur in a center experienced with MEN1 and pancreatic or duodenal neuroendocrine tumors.

Even after apparently successful surgery, gastrin, acid control, and imaging follow-up may continue. A person should not stop PPI treatment until the team confirms it is safe.

Treatment when disease has spread

Metastatic or unresectable gastrinoma may be managed with somatostatin analogues, targeted medicines, peptide receptor radionuclide therapy, liver-directed treatment, chemotherapy, surgery, or clinical trials depending on receptor status, grade, burden, symptoms, and growth.

These treatments address tumor control and are separate from acid suppression. Even when tumor-directed treatment works, the PPI plan may need to continue.

A neuroendocrine-tumor multidisciplinary team can integrate oncology, surgery, nuclear medicine, gastroenterology, endocrinology, genetics, radiology, pathology, and nutrition.

Diarrhea and nutrition

Diarrhea may improve dramatically when acid is controlled. Persistent diarrhea can also reflect infection, pancreatic insufficiency, bile-acid problems, medication, surgery, or another gastrointestinal disorder.

Weight loss and fat malabsorption may require dietitian support and laboratory assessment. Restrictive diets do not treat gastrin secretion and can worsen malnutrition.

Over-the-counter antidiarrheal medicine should not delay evaluation of bleeding, severe pain, dehydration, or infection. A nutrition or enzyme plan should be selected from the demonstrated cause.

Pregnancy and other procedures

Pregnancy planning should review acid control, imaging, medicine safety, tumor behavior, MEN1, and nutrition. Necessary treatment should not be stopped abruptly after a positive test.

Before surgery or any period when oral medicine is restricted, the anesthesia and gastroenterology teams need a plan to maintain acid suppression. Vomiting or inability to swallow may require an alternative route.

Monitoring over time

Follow-up can include symptoms, ulcer healing, PPI dose, fasting gastrin under controlled conditions, imaging, tumor markers selected by the team, nutrition, and MEN1 surveillance. A single gastrin rise can reflect medicine or testing conditions and should be confirmed.

Report recurrent pain, diarrhea, swallowing difficulty, bleeding, weight loss, jaundice, or new bone pain. Routine follow-up should continue even when symptoms are fully controlled.

Keep pathology, imaging, MEN1 testing, gastrin and pH results, surgery records, and exact PPI history because interpretation depends on the sequence.

Preparing for specialist care

Bring ulcer and endoscopy reports, H. pylori testing, NSAID use, fasting gastrin with PPI dose and timing, stomach pH or acid results, scans, pathology, calcium and parathyroid history, family history, diarrhea and weight timeline, and all medicines.

Ask whether high gastrin reflects acid overproduction, how medicine will be adjusted safely for testing, what evidence localizes a tumor, whether MEN1 evaluation is needed, and how acid and tumor control will be followed separately.

Common questions

Does a high gastrin result prove ZES?

No. PPIs, low stomach acid, kidney disease, and other conditions can raise gastrin. Stomach acidity and the full evaluation matter.

Can a person stop a PPI to make the test accurate?

Only under a specialist-supervised plan. Stopping can cause dangerous acid complications in true ZES.

Is every gastrinoma part of MEN1?

No. Most ZES is sporadic, while a significant minority is associated with MEN1. Personal and family features guide testing.

Can acid medicine cure the tumor?

No. It controls acid and prevents complications. Tumor-directed surgery or other treatment is assessed separately.

Can diarrhea be the only symptom?

Yes, but diarrhea is common and usually has another cause. ZES testing is selected from the broader clinical pattern.